Thu Sep 12 08:51:35 UTC 2024: ## Israeli Startup Discure Technologies Secures $11 Million to Treat Degenerative Disc Disease
**Tel Aviv, Israel –** Discure Technologies, an Israeli medical device company, has secured $11 million in Series A funding to advance its innovative treatment for degenerative disc disease (DDD). The funding round, led by BOLD Capital Partners, Supernova Invest, and Sanara Capital, brings the company’s total equity financing to $16 million.
Discure’s flagship product, the Discure System, is a minimally invasive, implantable bioelectronic device designed to treat and potentially reverse the progression of DDD. Unlike traditional treatments that focus on pain management, the Discure System aims to restore the disc’s natural function, addressing the underlying cause of the disease.
DDD is a common condition affecting the intervertebral discs in the spine, leading to pain, numbness, and potential muscle weakness. It is a significant cause of disability globally, with over 35% of low back pain cases attributed to DDD.
“This latest investment validates the Company’s novel, minimally invasive approach to reverse disc degeneration, shifting the paradigm from symptom management to addressing the problem by regenerating the disc,” said Yuval Mandelbaum, CEO of Discure Technologies.
The funding will be used to accelerate Discure’s growth, including key hires and the full funding of its First-in-Human clinical study in Canada and Italy. The company has already completed extensive pre-clinical testing, including studies in large animals and human cadaveric discs.
Discure’s innovative approach to treating DDD presents a significant opportunity to improve the lives of millions suffering from this debilitating condition.
First Piper 